Canada
EN FR

Africa

Asia Pacific

Europe

Middle East

North America

Latin America / Caribbean

South America

logo qulipta

  

Product Monograph
AbbVie Care Program
Important Safety Information
Clinical trial program

QULIPTA® (atogepant tablets) is indicated for the prevention of migraine in adults who have at least 4 migraine days per month.1

QULIPTA clinical trial program1

 

Clinical trial_table
Clinical trial_table-Mobile_x1

Safety information

Click here for additional safety information and for a link to the Product Monograph discussing:

●Relevant warnings and precautions regarding patients with severe hepatic impairment, driving and operating machinery, pregnant and nursing women, and geriatrics.

●Conditions of clinical use, adverse reaction, drug interactions and dosing instructions.

Reference:

    1. QULIPTA Product Monograph. AbbVie Corporation.

For more information

For any questions related to QULIPTA, you can contact AbbVie Medical Information at 1 844 241-5011.

 

QULIPTA and its design are trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company, used under license by AbbVie Corporation.
© 2024 AbbVie. All rights reserved.

 

For more information

For any questions related to QULIPTA, you can contact AbbVie Medical Information at
1 888 241-5011.

 

QULIPTA and its design are trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company, used under license by AbbVie Corporation.
© 2024 AbbVie. All rights reserved.

 

CA-QLP-240063A / OC24

This website is intended for Canadian Healthcare Professionals

Copyright® 2022 AbbVie Corporation. Canada. 

Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.